

Cell Cycle	CITED2	Cbp/p300-interacting transactivator, 2	93.8	75.75
	FCD1	FYVE, RhoGEF and PH domain containing 1	34.05	32.77
	CADM1	cell adhesion molecule 1	28.89	25.15
	BTG1	B-cell translocation gene 1, anti-proliferative	28.22	29.83
	MUSK	muscle, skeletal, receptor tyrosine kinase	15.02	15.34
	UBN1	ubinuclein 1	14.59	12.74
	EGFR	epidermal growth factor receptor	13.6	8.87
	RASSF2	Ras association (RalGDS/AF-4) domain family member 2	13.18	12.24
	ZER1	zer-1 homolog (<i>C. elegans</i>)	13.02	9.38
	FBXL7	F-box and leucine-rich repeat protein 7	12.91	8.11
	UBE2L6	ubiquitin-conjugating enzyme E2L 6	12.74	13.94
	HHR3	hect domain and RLD 3	12.09	6.18
	hCG_1998957	major histocompatibility complex, class II	11.93	15.31
	EDAR	ectodysplasin A receptor	11.73	13.88
	CDC2LS	cell division cycle 2-like 5	11.24	13.32
	CD40	CD40 molecule, TNF receptor superfamily member 5	10.97	9.25
	NHLH2	nascent helicase loop helix 2	10.93	12.87
	IFNALS	interferon, alpha 5	10.2	7.85
	CHFR	checkpoint with forkhead and ring finger domains	9.63	10.26
	CSNK1A1	casein kinase 1, alpha 1	9.19	11.27
	DMBT1	deleted in malignant brain tumors 1	9.17	11.55
	DDX3X	DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked	9.05	6.54
	PTP4A3	protein tyrosine phosphatase type IVA, member 3	8.89	9.27
	RECB	RECB homolog (<i>Saccharomyces cerevisiae</i>)	8.85	9.01
	EIF4G2	eukaryotic translation initiation factor 4 gamma, 2	8.8	7.38
	PRKY	protein kinase, Y-linked	8.75	6.91
	PER1	period homolog 1 (<i>Drosophila</i>)	8.67	7.44
	XIAP	X-linked inhibitor of apoptosis	8.64	9.14
	PML	promyelocytic leukemia	8.35	9.14
	LGH11CR2A	loss of heterozygosity, 11, chromosomal region 2, gene A	8.31	9.03
	HIST1H4G	histone cluster 1, H4g	8.07	12.14
	MYL4	myosin, light chain 4, alkali; atrial, embryonic	7.96	5.24
	XIST	X (inactive)-specific transcript (non-protein coding)	7.53	12.13
	FCXC1	forkhead box C1	7.5	6.58
	H2AFX	H2A histone family, member X	7.18	5.66
	BCL6	B-cell CLL/lymphoma 6 (zinc finger protein 51)	7.1	3.88
	PPIG	peptidylprolyl isomerase G (cyclophilin G)	7.06	8.36
	UBE2L3	ubiquitin-conjugating enzyme E2L 3	6.82	5.54
	BAX	BCL2-associated X protein	6.39	7.94
	UBE2D4	ubiquitin-conjugating enzyme E2D 4 (putative)	6.04	5.37
	HIST2H2AAE	histone cluster 2, H2be	5.99	6.36
	DGKA	diacylglycerol kinase, alpha SGKDa	5.98	6.92
	FBXW2	F-box and WD repeat domain containing 2	5.71	5.53
	HMGAL2	high mobility group AT-hook 2	5.62	7.86
	RAP1A	RAP1A, member of RAS oncogene family	5.58	3.37
	CUL3	cullin 3	5.56	6.5
	BRCC3	BRCA1/BRCA2-containing complex, subunit 3	5.46	6.73
	JARID1A	jumonji, AT rich interactive domain 1A	5.38	4.97
	UBE2Q1	ubiquitin-conjugating enzyme E2Q family member 1	5.26	6.82
	CBLB	Cas-Br-M (<i>murine</i>) oncogenic retroviral transforming sequence b	5.12	4.09
	ARG2	arginase, type II	5.01	3.95
	DDX5	DEAD (Asp-Glu-Ala-Asp) box polypeptide 5	4.87	4.55
	FANCC	Fanconi anemia, complementation group C	4.76	3.59
	CNOT3	CCR4-NOT transcription complex, subunit 3	4.72	4.7
	MID2	midline 2	4.72	4.12
	SOCS6	suppressor of cytokine signaling 6	4.7	4.91
	PARD6A	par-6 partitioning defective 6 homolog alpha (<i>C. elegans</i>)	4.67	4.33
	RANBP9	RAN binding protein 9	4.65	3.52
	BRE	brain and reproductive organ-expressed (TINERF1A modulator)	4.53	4.09
	GCAT	glycine C-methyltransferase (S-amino-3-ketobutyrate coenzyme A ligase)	4.51	3.35
	STAG2	stromal antigen 2	4.48	3.29

Wang *et al.*, Supplemental Table 1.